Trypanosoma cruzi chemical proteomics using immobilized benznidazole

Experimental Parasitology

Volumn 140, Issue 1, 2014, Pages 33-38

  Trochine, Andrea ^a   Alvarez, Guzmán ^b   Corre, Sandra ^a,e   Faral Tello, Paula ^a   Durán, Rosario ^a,c   Batthyany, Carlos I ^a,c,d   Cerecetto, Hugo ^b   González, Mercedes ^b   Robello, Carlos ^a,d  

^a INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^d DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^e INSTITUT PASTEUR   (France)

Author keywords

Aldo ketoreductases; Benznidazole; Chemical proteomics; TcAKR; Trypanosoma cruzi

Indexed keywords

BACTERIAL PROTEIN; BENZNIDAZOLE; COAT PROTEIN COMPLEX II; NITROREDUCTASE; PROTEIN SEC23A; PROTEIN YJEF; PROTOZOAL PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; COVALENT BOND; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEOMICS; STRUCTURE ANALYSIS; TRYPANOSOMA CRUZI;

ALDO-KETOREDUCTASES; BENZNIDAZOLE; CHEMICAL PROTEOMICS; TCAKR; TRYPANOSOMA CRUZI;

ALDEHYDE REDUCTASE; CHROMATOGRAPHY, AFFINITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MICROSPHERES; NITROIMIDAZOLES; PROTEOMICS; PROTOZOAN PROTEINS; SEPHAROSE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; TUBULIN;

EID: 84896958580     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2014.03.013     Document Type: Article

References (37)

1. Andrade H.M., Murta S.M., Chapeaurouge A., Perales J., Nirde P., Romanha A.J. Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. J. Proteome Res. 2008, 7:2357-2367.
2. Andrade S.G., Magalhaes J.B., Pontes A.L. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull. World Health Organ. 1985, 63:721-726.
3. Baker N., Alsford S., Horn D. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol. Biochem. Parasitol. 2011, 176:55-57.
4. Barlowe C., Orci L., Yeung T., Hosobuchi M., Hamamoto S., Salama N., Rexach M.F., Ravazzola M., Amherdt M., Schekman R. COPII: a membrane coat formed by Sec proteins that drive vesicle budding from the endoplasmic reticulum. Cell 1994, 77:895-907.
5. Brisse S., Dujardin J.C., Tibayrenc M. Identification of six Trypanosoma cruzi lineages by sequence-characterised amplified region markers. Mol. Biochem. Parasitol. 2000, 111:95-105.
6. Camargo E.P. Growth and differentiation in Trypanosoma Cruzi. I. Origin of metacyclic trypanosomes in liquid media. Rev. Inst. Med. Trop. Sao Paulo 1964, 6:93-100.
7. Contreras V.T., Araujo-Jorge T.C., Bonaldo M.C., Thomaz N., Barbosa H.S., Meirelles Mde N., Goldenberg S. Biological aspects of the Dm 28c clone of Trypanosoma cruzi after metacyclogenesis in chemically defined media. Mem. Inst. Oswaldo Cruz 1988, 83:123-133.
8. Diaz de Toranzo E.G., Castro J.A., Franke de Cazzulo B.M., Cazzulo J.J. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia 1988, 44:880-881.
9. Docampo R., Stoppani A.O. Mechanism of the trypanocidal action of nifurtimox and other nitro-derivatives on Trypanosoma cruzi. Medicina (B Aires) 1980, 40(Suppl. 1):10-16.
10. Garavaglia P.A., Cannata J.J., Ruiz A.M., Maugeri D., Duran R., Galleano M., Garcia G.A. Identification, cloning and characterization of an aldo-keto reductase from Trypanosoma cruzi with quinone oxido-reductase activity. Mol. Biochem. Parasitol. 2010, 173:132-141.
11. Grunewald G.L., Romero F.A., Criscione K.R. 3-Hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display remarkable potency and selectivity. J. Med. Chem. 2005, 48:134-140.
12. Hall B.S., Bot C., Wilkinson S.R. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 2011, 286:13088-13095.
13. Hall B.S., Meredith E.L., Wilkinson S.R. Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs. Antimicrob. Agents Chemother 2012, 56:5821-5830.
14. Hall B.S., Wilkinson S.R. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. 2012, 56:115-123.
15. Komoto J., Yamada T., Watanabe K., Takusagawa F. Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 2004, 43:2188-2198.
16. Kubata B.K., Kabututu Z., Nozaki T., Munday C.J., Fukuzumi S., Ohkubo K., Lazarus M., Maruyama T., Martin S.K., Duszenko M., Urade Y. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J. Exp. Med. 2002, 196:1241-1251.
17. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
18. Marbaix A.Y., Noel G., Detroux A.M., Vertommen D., Van Schaftingen E., Linster C.L. Extremely conserved ATP- or ADP-dependent enzymatic system for nicotinamide nucleotide repair. J. Biol. Chem. 2011, 286:41246-41252.
19. Marin-Neto J.A., Rassi A., Avezum A., Mattos A.C., Rassi A., Morillo C.A., Sosa-Estani S., Yusuf S. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz 2009, 104(Suppl. 1):319-324.
20. Maya J.D., Cassels B.K., Iturriaga-Vasquez P., Ferreira J., Faundez M., Galanti N., Ferreira A., Morello A. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 2007, 146:601-620.
21. Maya J.D., Repetto Y., Agosin M., Ojeda J.M., Tellez R., Gaule C., Morello A. Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Mol. Biochem. Parasitol. 1997, 86:101-106.
22. Menna-Barreto R.F., Belloze K.T., Perales J., Silva-Jr F.P. Proteomic and Bioinformatic Analysis of Trypanosoma Cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle. Curr. Drug Targets 2014, 15:255-271.
23. Murta S.M., Krieger M.A., Montenegro L.R., Campos F.F., Probst C.M., Avila A.R., Muto N.H., de Oliveira R.C., Nunes L.R., Nirde P., Bruna-Romero O., Goldenberg S., Romanha A.J. Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol. Biochem. Parasitol. 2006, 146:151-162.
24. Paba J., Santana J.M., Teixeira A.R., Fontes W., Sousa M.V., Ricart C.A. Proteomic analysis of the human pathogen Trypanosoma cruzi. Proteomics 2004, 4:1052-1059.
25. Parodi-Talice A., Duran R., Arrambide N., Prieto V., Pineyro M.D., Pritsch O., Cayota A., Cervenansky C., Robello C. Proteome analysis of the causative agent of Chagas disease: Trypanosoma cruzi. Int. J. Parasitol. 2004, 34:881-886.
26. Parodi-Talice A., Monteiro-Goes V., Arrambide N., Avila A.R., Duran R., Correa A., Dallagiovanna B., Cayota A., Krieger M., Goldenberg S., Robello C. Proteomic analysis of metacyclic trypomastigotes undergoing Trypanosoma cruzi metacyclogenesis. J. Mass Spectrom. 2007, 42:1422-1432.
27. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
28. Rassi A., Rassi A., Marin-Neto J.A. Chagas disease. Lancet 2010, 375:1388-1402.
29. Remme J.H.F., Feenstra P., Lever P.R., Medici A.C., Morel C.M., Noma M., Ramaiah K.D., Richards F., Seketeli A., Schmunis G., van Brakel W.H., Vassall A. Tropical Diseases Targeted for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy. Disease Control Priorities in Developing Countries 2006, 433-449. World Bank, Washington, DC, (Chapter 22). second ed. D.T. Jamison, J.G. Breman, A.R. Measham, G. Alleyne, M. Claeson, D.B. Evans, P. Jha, A. Mills, P. Musgrove (Eds.).
30. Schofield C.J., Jannin J., Salvatella R. The future of Chagas disease control. Trends Parasitol. 2006, 22:583-588.
31. Sevova E.S., Bangs J.D. Streamlined architecture and glycosylphosphatidylinositol-dependent trafficking in the early secretory pathway of African trypanosomes. Mol. Biol. Cell 2009, 20:4739-4750.
32. Terstappen G.C., Schlupen C., Raggiaschi R., Gaviraghi G. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 2007, 6:891-903.
33. Urbina J.A. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010, 115:55-68.
34. Wilkinson S.R., Bot C., Kelly J.M., Hall B.S. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr. Top. Med. Chem. 2011, 11:2072-2084.
35. Wilkinson S.R., Kelly J.M. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev. Mol. Med. 2009, 11:e31.
36. Wilkinson S.R., Taylor M.C., Horn D., Kelly J.M., Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U.S.A 2008, 105:5022-5027.
37. Yamaguchi K., Okamoto N., Tokuoka K., Sugiyama S., Uchiyama N., Matsumura H., Inaka K., Urade Y., Inoue T. Structure of the inhibitor complex of old yellow enzyme from Trypanosoma cruzi. J. Synchrotron Radiat. 2011, 18:66-69.